Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

The antifungal efficacy, safety, and pharmacokinetics of posaconazole (SCH 56592) (POC) were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Antifungal therapy consisted of POC at 2, 6, and 20 mg/kg of bod...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Petraitiene, Ruta, Petraitis, Vidmantas, Groll, Andreas H., Sein, Tin, Piscitelli, Stephen, Candelario, Myrna, Field-Ridley, Aida, Avila, Nilo, Bacher, John, Walsh, Thomas J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2001
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC90385/
https://ncbi.nlm.nih.gov/pubmed/11181372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.45.3.857-869.2001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires